In January 2024, the FDA announced it was investigating semaglutide for several potential safety signals, including blood clots, alongside hair loss, aspiration risk, and suicidal ideation
This research provides a compelling new framework for addressing the neurological and digestive symptoms of MCAS, giving clinicians a pathway to support patients experiencing chronic immune-nervous system cross-activation
The appetite suppression makes hitting protein targets difficult, requiring deliberate meal planning
Beyond bioactive constituents and overall dietary patterns, certain dietary strategies, such as the ketogenic diet, may influence neurocognitive outcomes by deliberately shifting systemic metabolism towards physiological ketosis, thereby increasing circulating ketone bodies and providing a distinct mechanistic framework [67, 68]